<DOC>
	<DOC>NCT01232595</DOC>
	<brief_summary>This study will assess the safety and efficacy of multiple daily dosing of oral LFF571 in patients who have moderate Clostridium difficile infections.</brief_summary>
	<brief_title>Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Males and females between 18 and 90 years of age, inclusive. Diagnosed with primary episode or first relapse of moderate C. difficile infection. Received â‰¤24 hours of therapy effective for C. difficile infection prior to enrollment. Severe C. difficile infection Expected to require more than 10 days of C. difficile infection treatment. More than one prior episode of C. difficile infection within the prior 3 months. Use of antiperistaltic drugs (including tincture of opium, metoclopramide, loperamide),, cholestyramine, or colestipol Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Clostridium difficile,</keyword>
	<keyword>C. difficile,</keyword>
	<keyword>CDI,</keyword>
	<keyword>Clostridium difficile-associated disease,</keyword>
	<keyword>CDAD,</keyword>
	<keyword>pseudomembranous colitis,</keyword>
	<keyword>PMC,</keyword>
	<keyword>antibiotic-associated diarrhea</keyword>
</DOC>